



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Hexacima

Procedural steps taken and scientific information after the authorisation

| Application number | Scope | Opinion/ Notification ¹ issued on | Commission Decision Issued ² / amended on | Product Information affected ³ | Summary |
|--------------------|---|--|--|---|---------|
| T/0162 | Transfer of Marketing Authorisation | 23/10/2024 | 04/12/2024 | SmPC, Labelling and PL | |
| WS/2755 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 07/11/2024 | n/a | | |

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



| | | | | | |
|-----------|--|------------|-----|--|--|
| | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | | | | |
| WS/2692/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP</p> | 10/10/2024 | n/a | | |
| WS/2716/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.z - Change in the specification parameters</p> | 05/09/2024 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|------------------------------|--|
| | and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | | | | |
| WS/2634 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 11/07/2024 | n/a | | |
| WS/2633/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking | 18/04/2024 | 04/12/2024 | SmPC, Labelling and PL | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| WS/2635 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.z - Change in control of the AS - Other variation</p> | 21/03/2024 | n/a | | |
| WS/2616/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.z - Change in control of the AS - Other variation</p> <p>B.I.b.z - Change in control of the AS - Other variation</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance</p> | 15/02/2024 | n/a | | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| | <p>which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> | | | | |
| WS/2525/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.b.z - Change in control of the AS - Other variation</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The</p> | 16/11/2023 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|------------------------------|--|
| | proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | | | | |
| WS/2532/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> | 28/09/2023 | n/a | | |
| WS/2495 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 13/07/2023 | n/a | | |
| WS/2468/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with</p> | 22/06/2023 | 01/02/2024 | SmPC, Labelling and PL | |

| | | | | | |
|---------|--|------------|-----|--|--|
| | <p>its corresponding test method</p> <p>B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> | | | | |
| WS/2469 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 15/06/2023 | n/a | | |
| WS/2479 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> | 08/06/2023 | n/a | | |
| WS/2412 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> | 01/06/2023 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|------------------------|--|
| | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | | | | |
| WS/2401/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product</p> <p>B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs</p> | 12/05/2023 | n/a | | |
| WS/2433 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> | 26/04/2023 | n/a | | |
| WS/2326/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 23/02/2023 | 01/02/2024 | SmPC, Labelling and PL | <p>As a result of this variation, section 2 the SmPC has been updated to adjust of the poliovirus D antigen levels:</p> <p>Poliovirus (Inactivated)⁵</p> <p>Type 1 (Mahoney) 29 D-antigen units⁶</p> |

| | | | | | |
|---------|---|------------|-----|--|---|
| | <p>B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | | | | <p>Type 2 (MEF-1) 7 D-antigen units6</p> <p>Type 3 (Saukett) 26 D-antigen units6</p> <p>5 Cultivated on Vero cells</p> <p>6 These antigen quantities are strictly the same as those previously expressed as 40-8-32 D-antigen units, for virus type 1, 2 and 3 respectively, when measured by another suitable immunochemical method.</p> <p>The Package Leaflet (PL) is updated accordingly.</p> |
| WS/2381 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 26/01/2023 | n/a | | |
| WS/2394 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | 26/01/2023 | n/a | | |

| | | | | | |
|---------------------|---|------------|------------|------------------|-----------------------------------|
| WS/2345 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p> | 08/12/2022 | n/a | | |
| PSUSA/10091 /202204 | <p>Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccines (adsorbed)</p> | 01/12/2022 | n/a | | PRAC Recommendation - maintenance |
| WS/2239/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> | 01/12/2022 | n/a | | |
| N/0139 | <p>Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)</p> | 08/11/2022 | 15/03/2023 | Labelling and PL | |

| | | | | | |
|-----------|---|------------|------------|-------------|--|
| IG/1559 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking | 24/10/2022 | n/a | | |
| WS/2309/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> | 22/09/2022 | 15/03/2023 | SmPC and PL | |
| WS/2313 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | 15/09/2022 | n/a | | |
| WS/2138/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 01/09/2022 | n/a | | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| | <p>B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | | | | |
| WS/2282 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 21/07/2022 | n/a | | |
| WS/2272/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> | 07/07/2022 | n/a | | |

| | | | | | |
|---------|---|------------|------------|-------------|---|
| WS/2262 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 23/06/2022 | n/a | | |
| WS/2245 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product</p> | 02/06/2022 | n/a | | |
| WS/2233 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation</p> | 22/04/2022 | n/a | | |
| WS/2174 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.5 of the SmPC in order to add drug-drug interaction information regarding the co-administration of Hexyon / Hexacima with varicella</p> | 24/03/2022 | 15/03/2023 | SmPC and PL | <p>The MAH presented a new analysis of the serological data of clinical study A3L15(based on a different definition for seroresponse) on the co-administration of varicella vaccines with the hexavalent DTaP-IPVHB-PRP~Ta vaccines Hexacima and Hexyon. This analysis showed that these vaccines can be co-administered with varicella vaccines. The Product information for Hexacima and Hexyon has</p> |

| | | | | | |
|-----------|---|------------|-----|--|---|
| | <p>vaccines based on a re-analysis of the A3L15 clinical trial varicella serological data, submitted in the initial CTD dossier. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct some typo errors in the SmPC and PL.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | | | | <p>been updated to reflect the above findings.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p> |
| WS/2148/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 10/02/2022 | n/a | | |
| WS/2188/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No</p> | 13/01/2022 | n/a | | |

| | | | | | |
|---------|---|------------|-----|--|--|
| | <p>1234/2008.</p> <p>B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | | | | |
| IG/1465 | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State | 14/12/2021 | n/a | | |
| WS/2139 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 02/12/2021 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|----|--|
| N/0125 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 15/11/2021 | 15/03/2023 | PL | |
| WS/2112 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 28/10/2021 | n/a | | |
| WS/2101 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 02/09/2021 | n/a | | |
| WS/2080/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | 22/07/2021 | n/a | | |

| | | | | | |
|---------|---|------------|-----|--|--|
| | <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | | | | |
| WS/2033 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p> | 24/06/2021 | n/a | | |
| WS/1930 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> | 28/05/2021 | n/a | | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| WS/2034 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 15/04/2021 | n/a | | |
| WS/2005/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 18/03/2021 | n/a | | |
| WS/2001 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant</p> | 11/03/2021 | n/a | | |

| | | | | | |
|-----------|---|------------|------------|-------------|--|
| | effect on the overall quality of the finished product | | | | |
| WS/1926/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> | 25/02/2021 | n/a | | |
| WS/1965/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 18/02/2021 | 24/06/2021 | SmPC and PL | The persistence of the immune responses against the hepatitis B component of Hexyon/Hexacima was evaluated in infants. For a 2-dose primary infant series at 3 and 5 months of age without hepatitis B at birth, followed by a |

| | | | | | |
|--|---|--|--|--|---|
| | <p>C.I.4 (type II): Update of section 5.1 of the SmPC in order to describe the persistence of anti-HBs antibodies in subjects 6 years of age having received a hexavalent vaccine based on the final results from study A3L00052; this is a phase IV, open-label, multi-centre study in children previously vaccinated in Study A3L38a with 3 doses of either Hexacima/Hexyon (Group 1) or Infanrix Hexa (Group 2).</p> <p>C.I.4 (type II): Update of sections 4.4 and 5.1 of the SmPC in order to reword safety and immunogenicity information regarding individuals with immunodeficiency based on the final results from study A3L44; this is a Phase III, single centre, open-label, two-arm study including HIV-exposed infected and uninfected infants vaccinated with a 3-dose infant primary series (at 6, 10, and 14 weeks of age) and a booster dose (at 15 to 18 months of age) with Hexacima/Hexyon in Republic of South Africa. The updates to the SmPC were requested following assessment of these data by Article 46, EMEA/H/C/002702/P46/036 (Hexacima) and EMEA/H/C/002796/P46/034 (Hexyon).</p> <p>C.I.z (type IB): Updated of section 4.4 of the SmPC in order to include syncope within the precautions for use. The package leaflet is updated accordingly. In addition, the WSA took the opportunity to update the list of local representatives in the Package Leaflet.</p> | | | | <p>toddler booster at 11-12 months of age, 53.8% of children were seroprotected (anti-HBsAg \geq 10 mIU/mL) at 6 years of age, and 96.7% presented an anamnestic response after a challenge dose with a standalone Hepatitis B vaccine. These data support persisting immune memory induced in infants primed with Hexyon/Hexacima.</p> <p>Immunogenicity data in HIV-exposed infants (infected and uninfected) showed that Hexyon//Hexacima is immunogenic in the potentially immunodeficient population of HIV-exposed infants whatever their HIV status at birth. No specific safety concern was observed in this population.</p> <p>Inclusion of syncope within the precautions for use. Syncope can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent falling and injury and to manage syncope.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p> |
|--|---|--|--|--|---|

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>In addition, the WSA took the opportunity to update the product information according to QRD-template 10.1.</p> <p>The RMP version 13.0 has also been submitted.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p> | | | | |
| WS/1991 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> | 11/02/2021 | n/a | | |
| WS/1957/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting</p> | 21/01/2021 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> | | | | |
| WS/1959 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method</p> | 14/01/2021 | n/a | | |
| WS/1906/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal</p> | 10/12/2020 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | product and is not related to a protocol B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation | | | | |
| WS/1904/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p> <p>B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> | 15/10/2020 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|-------------|---|
| WS/1792/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.4 (type II) - Update of sections 4.4 and 5.1 of the SmPC in order to revise the warning regarding preterm infants and to add new information on immunogenicity in preterm infants and in infants born from women vaccinated during pregnancy, based on the final results from study A3L00053-EXT; this is an observational cohort study conducted by the Center for the Evaluation of Vaccination in Vaccine and Infectious Diseases Institute of University of Antwerp with DTaP-IPV-HB-PRP~T vaccine, aimed to describe the concentrations of IgG against the different antigens. The RMP version 12.0 has been submitted an updated accordingly, following revision 2 with consequential update to the safety concerns.</p> <p>C.I.z (type IB) - Update of sections 2 and 4.4 of the SmPC in order to add warning for excipients with known effect: phenylalanine, potassium and sodium, according to the European guideline "Excipients in the labeling and package leaflet of medicinal products for human use SANTE-2017-11668". The package leaflet is updated accordingly.</p> <p>In addition, the MAH/SOH took the opportunity to introduce editorial changes in sections 4.2, 4.4, 4.5 and 4.8 of the SmPC and to update the list of local</p> | 24/09/2020 | 24/06/2021 | SmPC and PL | <p>Based on data generated from study A3L00053-EXT, immunogenicity data have been made available for 105 preterm infants (born after a gestation period of 28 to 36 weeks). These data support the use of Hexacima/Hexaxim/Hexyon in preterm infants. As expected in preterm infants, lower immune response has been observed for some antigens, when indirectly compared to term infants, although seroprotective levels have been achieved. Immune responses to Hexacima/Hexaxim/Hexyon in infants born (preterm and term) to women vaccinated with Tdap (tetanus, diphtheria and acellular pertussis) during pregnancy were included in the product information. The rate of seroprotected prior to their own primary vaccination is lower in the pre-term born. Nevertheless, a benefit of the maternal immunization is seen for both groups.</p> <p>The data shown for the Pertussis antigens show that the maternal immunization results in higher geometric mean concentrations (GMCs) in the infants regardless of pre-term status and after the primary and booster immunization all GMCs are similar regardless of vaccination group. The fold increases due to primary immunization are lower in the maternally-vaccinated.</p> <p>For more information, please refer to the Summary of Product Characteristics.</p> |
|-----------|--|------------|------------|-------------|---|

| | | | | | |
|-----------|--|------------|-----|--|--|
| | <p>representatives in the Package Leaflet.</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | | | | |
| WS/1872/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> | 17/09/2020 | n/a | | |
| WS/1784/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> | 17/09/2020 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> | | | | |
| WS/1797/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal</p> | 03/09/2020 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | product and is not related to a protocol B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits | | | | |
| WS/1839/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation | 23/07/2020 | n/a | | |
| WS/1815/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 16/07/2020 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|------|--|
| WS/1802 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | 16/07/2020 | n/a | | |
| WS/1786 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> | 02/07/2020 | n/a | | |
| WS/1821/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p> | 25/06/2020 | 24/06/2021 | SmPC | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation | | | | |
| WS/1699 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> | 27/02/2020 | n/a | | |
| WS/1744/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p> <p>B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant</p> | 06/02/2020 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>effect on the overall quality of the AS and/or the FP</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p> | | | | |
| WS/1728/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.z - Change in the specification parameters</p> | 23/01/2020 | n/a | | |

| | | | | | |
|---------------------|---|------------|-----|--|-----------------------------------|
| | and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | | | | |
| PSUSA/10091 /201904 | Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccines (adsorbed) | 31/10/2019 | n/a | | PRAC Recommendation - maintenance |
| WS/1623 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.z - Quality change - Active substance - Other variation | 18/07/2019 | n/a | | |
| WS/1624/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change | 04/07/2019 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>in the manufacturing process</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> | | | | |
| WS/1592/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> | 14/06/2019 | n/a | | |
| WS/1575/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting</p> | 29/05/2019 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|------------------------------|--|
| | material/intermediate/reagent - Other variation | | | | |
| WS/1574 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> | 26/04/2019 | n/a | | |
| WS/1525 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 11/04/2019 | n/a | | |
| WS/1496/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a</p> | 28/03/2019 | | SmPC, Labelling and PL | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| | biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol | | | | |
| WS/1455/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 17/01/2019 | n/a | | |
| WS/1438/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the</p> | 06/12/2018 | n/a | | |

| | | | | |
|---|--|--|--|--|
| <p>manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p> <p>B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)</p> | | | | |
|---|--|--|--|--|

| | | | | | |
|--------------------|--|------------|-----|--|-----------------------------------|
| WS/1393/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | 22/11/2018 | n/a | | |
| PSUSA/10091/201804 | Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccines (adsorbed) | 31/10/2018 | n/a | | PRAC Recommendation - maintenance |
| WS/1394 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> | 27/09/2018 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| WS/1353/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 20/09/2018 | n/a | | |
| WS/1350 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 28/06/2018 | n/a | | |
| WS/1304 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation</p> | 19/04/2018 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| WS/1281/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> | 12/04/2018 | n/a | | |
| WS/1306 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> | 22/03/2018 | n/a | | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| WS/1303/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | 22/02/2018 | n/a | | |
| WS/1286 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 01/02/2018 | n/a | | |
| WS/1233/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting</p> | 01/02/2018 | n/a | | |

| | | | | | |
|-----------|---|------------|------------|----------------------------------|--|
| | <p>material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | | | | |
| R/0068 | Renewal of the marketing authorisation. | 09/11/2017 | 08/01/2018 | SmPC and PL | |
| IG/0869 | A.1 - Administrative change - Change in the name and/or address of the MAH | 08/12/2017 | 17/12/2018 | SmPC, Annex II, Labelling and PL | |
| WS/1185/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> | 16/11/2017 | n/a | | |

| | | | | | |
|---------------------|---|------------|-----|--|-----------------------------------|
| WS/1231 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 02/11/2017 | n/a | | |
| PSUSA/10091 /201704 | <p>Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccines (adsorbed)</p> | 26/10/2017 | n/a | | PRAC Recommendation - maintenance |
| IG/0854/G | <p>This was an application for a group of variations.</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-</p> | 20/10/2017 | n/a | | |

| | | | | |
|--|--|--|--|--|
| significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
| B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |

| | | | | | |
|--|---|--|--|--|--|
| | <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> | | | | |
|--|---|--|--|--|--|

| | | | | | |
|---|--|--|--|--|--|
| <p>an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> | | | | | |
| <p>B.I.b.1.d - Change in the specification parameters</p> | | | | | |

| | | | | |
|---|--|--|--|--|
| and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | | | | |
|---|--|--|--|--|

| | | | | |
|---|--|--|--|--|
| <p>significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> | | | | |
|---|--|--|--|--|

| | | | | | |
|---------|---|------------|-----|--|--|
| | <p>B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.III.2.c - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur.</p> | | | | |
| WS/1192 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> | 14/09/2017 | n/a | | |
| WS/1081 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> | 20/07/2017 | n/a | | |
| WS/1153 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or</p> | 13/07/2017 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | | | | |
| WS/1122/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits</p> | 13/07/2017 | n/a | | |
| WS/1174 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation</p> | 09/06/2017 | n/a | | |
| WS/1112 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 01/06/2017 | n/a | | |

| | | | | | |
|-----------|---|------------|------------|------|---|
| IG/0803 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 17/05/2017 | n/a | | |
| WS/1129/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> <p>B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation</p> | 11/05/2017 | n/a | | |
| WS/1148/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.3.z – To include the information about sequential schedule of hexavalent and pentavalent vaccines in primary series in section 4.2 of SmPC following the assessment of A3L39 study.</p> <p>C.I.4 - Update of section 5.1 of the SmPC in order to include data on persistence of immunity following final results from studies: A3L47: Laboratory analysis on sera stored at Sanofi Pasteur Global Clinical Immunology laboratory and collected within the</p> | 21/04/2017 | 08/01/2018 | SmPC | <p>Section 4.2 of SmPC has been amended to include the information on sequential schedule of hexavalent and pentavalent vaccines in primary series: 'When a dose of hepatitis B vaccine is given at birth, the sequential infant primary vaccination hexavalent/pentavalent/hexavalent schedule with Hexaxim/Hexyon/Hexacima and a pentavalent DTaP-IPV/Hib vaccine can be used in accordance with official recommendations.'</p> <p>Section 5.2 has been updated to include information on Persistence of immune response please see the SmPC for details.</p> |

| | | | | | |
|---------|---|------------|------------|------|--|
| | <p>context of trial PNA19 and A3L49: Phase III, multi-center study in children vaccinated with Hep B vaccine at birth followed by three infant primary series doses of Hexaxim® or Infanrix® hexa in A3L12 study in Thailand</p> <p>C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | | | | |
| WS/1146 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation</p> | 21/04/2017 | 08/01/2018 | SmPC | |
| WS/1071 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR</p> | 19/01/2017 | n/a | | |

| | | | | | |
|-----------|---|------------|------------|----|--|
| N/0056 | <p>Update of the package leaflets with revised contact details of the local representatives for BE, BG, LU, DA, DE, NL, NO, EL, AT, ES, FR, PT, IE, IS, IT, FI, SE, and UK.</p> <p>Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)</p> | 03/01/2017 | 11/04/2017 | PL | |
| WS/0922/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other</p> | 15/12/2016 | n/a | | |

| | | | | | |
|--------------------|--|------------|-----|--|-----------------------------------|
| | <p>variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation</p> | | | | |
| WS/0964/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | 10/11/2016 | n/a | | |
| PSUSA/10091/201604 | <p>Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate</p> | 27/10/2016 | n/a | | PRAC Recommendation - maintenance |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | vaccines (adsorbed) | | | | |
| WS/0967 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | 13/10/2016 | n/a | | |
| IG/0732/G | <p>This was an application for a group of variations.</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> | 20/09/2016 | n/a | | |
| WS/0918/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a</p> | 15/09/2016 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | | | | |
| WS/0838/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation</p> | 04/08/2016 | n/a | | |
| WS/0913/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> | 19/05/2016 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | | | | |
| WS/0912/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor</p> | 12/05/2016 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|------|--|
| | <p>changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> | | | | |
| WS/0907 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | 28/04/2016 | 11/04/2017 | SmPC | |
| WS/0901/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product</p> | 14/04/2016 | n/a | | |

| | | | | | |
|---------|--|------------|------------|----|--|
| | B.I.d.z - Stability of AS - Other variation | | | | |
| WS/0885 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> | 07/04/2016 | n/a | | |
| WS/0874 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 01/04/2016 | n/a | | |
| WS/0853 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 11/02/2016 | n/a | | |
| N/0044 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 03/02/2016 | 13/05/2016 | PL | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | | | | | |
| WS/0869 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products</p> | 14/01/2016 | n/a | | |
| WS/0832/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> | 10/12/2015 | n/a | | |
| WS/0797/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> | 03/12/2015 | n/a | | |

| | | | | | |
|--------------------|---|------------|------------|-------------|---|
| WS/0842 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> | 26/11/2015 | n/a | | |
| WS/0789 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC, upon request by PRAC following the assessment of PSUSA/10091/201410, to include 'convulsion with or without fever' and 'anaphylactic reaction' as ADRs. The Package Leaflet has been updated accordingly. In addition, for Hexyon the WSA took the opportunity to update the contact details for the local representative in Romania in the Package Leaflet. An updated RMP version 10.0 was agreed during the procedure.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | 19/11/2015 | 13/05/2016 | SmPC and PL | This variation application has been submitted in order to include 'convulsions with or without fever' and 'anaphylactic reactions' for the DTaP-IPV-HB-PRP-T hexavalent vaccine (Hexyon, Hexacima, Hexaxim) as adverse reactions reported during commercial use in section 4.8 of the SmPC with a frequency classification of 'rare'. 'Convulsions with or without fever' and 'anaphylactic reactions' were already listed in section 4.8 of the SmPC as potential adverse events (i.e. adverse events which have been reported with other vaccines). |
| PSUSA/10091/201504 | Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis | 06/11/2015 | n/a | | PRAC Recommendation - maintenance |

| | | | | | |
|---------|--|------------|-----|--|--|
| | toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccines (adsorbed) | | | | |
| WS/0796 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material</p> | 01/10/2015 | n/a | | |
| IG/0618 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 23/09/2015 | n/a | | |
| WS/0773 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> | 17/09/2015 | n/a | | |
| WS/0729 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 17/09/2015 | n/a | | |

| | | | | | |
|-----------|---|------------|------------|----|--|
| | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | | | | |
| N/0033 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 30/07/2015 | 13/05/2016 | PL | |
| IG/0587 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 15/07/2015 | n/a | | |
| IG/0579/G | <p>This was an application for a group of variations.</p> <p>B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method</p> | 29/06/2015 | n/a | | |
| WS/0568/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the</p> | 25/06/2015 | n/a | | |

| | | | | | |
|-----------|--|------------|-----|--|--|
| | <p>manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.c.1.b - Change in immediate packaging of the AS</p> <p>- Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> | | | | |
| WS/0749/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance</p> | 04/06/2015 | n/a | | |

| | | | | | |
|---------|--|------------|------------|-------------|---|
| | <p>which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | | | | |
| IG/0563 | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer | 27/05/2015 | n/a | | |
| IG/0561 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 27/05/2015 | n/a | | |
| WS/0702 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.5 and 5.1 of the SmPC in order to add the information on co-administration of the hexavalent vaccine with meningococcal serogroup C vaccine. The Package Leaflet is updated accordingly. The MAH took also the opportunity to make minor</p> | 21/05/2015 | 13/05/2016 | SmPC and PL | In this variation the Product information has been updated with the information that co-administration of the hexavalent vaccine with meningococcal serogroup C vaccine does not lead to any clinically relevant interference in the antibody response to each of the antigens. |

| | | | | | |
|--------------------|--|------------|-----|--|-----------------------------------|
| | <p>editorial changes throughout the PI.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | | | | |
| IG/0556 | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 13/05/2015 | n/a | | |
| PSUSA/10091/201410 | Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis antigens (pertussis toxoid, filamentous haemagglutinin) (acellular, component) / hepatitis b (rdna) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccines (adsorbed) | 07/05/2015 | n/a | | PRAC Recommendation - maintenance |
| WS/0727/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> | 23/04/2015 | n/a | | |

| | | | | | |
|-----------|--|------------|------------|-------------|---|
| WS/0678/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> | 26/03/2015 | n/a | | |
| WS/0677 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol</p> | 26/02/2015 | n/a | | |
| WS/0676 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 22/01/2015 | 24/02/2015 | SmPC and PL | Analysis of data provided in study A3L38 confirm that administration of two doses (with an interval of at least 8 weeks) or three doses (with an interval of at least 4 |

| | | | | | |
|-----------|--|------------|-----|--|---|
| | <p>Update of sections 4.2 and 5.1 of the SmPC with regards to 2+1 vaccination schedule combining a 2 dose priming series with a booster vaccination, further to the results of Phase III Study A3L38 conducted in healthy infants and toddlers (MEA 005). The package leaflet is updated accordingly. The MAH has taken also the opportunity to revise information of the local representative for Croatia in Hexacima PL, and to bring in line the PL for Hexaxim with the latest QRD v.9.0.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p> | | | | <p>weeks), in accordance with the official recommendations, together with one booster dose are capable of providing an adequate antibody response against each valence. No new safety concern with Hexacima/Hexyon administered in a 2+1 schedule emerged during the course of study A3L38.</p> |
| WS/0652/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Changes to the manufacturing process of the active substance (IPV)</p> <p>B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal</p> | 18/12/2014 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|--|
| | <p>product and is not related to a protocol</p> <p>B.I.c.1.b - Change in immediate packaging of the AS</p> <p>- Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> | | | | |
| WS/0594/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State</p> <p>B.III.2.b - Change to comply with Ph. Eur. or with a</p> | 18/12/2014 | n/a | | |

| | | | | | |
|-----------|---|------------|-----|--|-----------------------------------|
| | national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State | | | | |
| WS/0617/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> | 20/11/2014 | n/a | | |
| PSUV/0011 | Periodic Safety Update | 06/11/2014 | n/a | | PRAC Recommendation - maintenance |
| IAIN/0014 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 16/10/2014 | n/a | | |
| WS/0580 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 24/07/2014 | n/a | | |

| | | | | | |
|-----------|--|------------|-----|--|-----------------------------------|
| | <p>changes to the manufacturing process of the active substance</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> | | | | |
| WS/0531 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> | 26/06/2014 | n/a | | |
| PSUV/0006 | Periodic Safety Update | 08/05/2014 | n/a | | PRAC Recommendation - maintenance |
| WS/0547 | <p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Change in test procedures for the active substance.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> | 25/04/2014 | n/a | | |
| PSUV/0003 | Periodic Safety Update | 09/01/2014 | n/a | | PRAC Recommendation - maintenance |

| | | | | | |
|-----------|---|------------|------------|-------------|--|
| IG/0372 | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State | 13/11/2013 | n/a | | |
| IAIN/0004 | C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring | 11/11/2013 | 30/10/2014 | SmPC and PL | |
| WS/0462/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting</p> | 24/10/2013 | n/a | | |

| | | | | |
|---|--|--|--|--|
| <p>material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance</p> | | | | |
|---|--|--|--|--|

| | | | | |
|--|--|--|--|--|
| <p>which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p> <p>B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> | | | | |
|--|--|--|--|--|

| | | | | | |
|-----------|--|------------|-----|--|--|
| | <p>B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p> <p>B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation</p> | | | | |
| WS/0431/G | <p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products.</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products.</p> | 19/09/2013 | n/a | | |